Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin - Wikidata - awgldk - TriplyDB

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin

http://www.wikidata.org/entity/Q28275451

about

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers Identification of novel autoantibodies for detection of malignant mesothelioma Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma Malignant pleural mesothelioma: an update on diagnosis and treatment options.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.Biomarkers for malignant pleural mesothelioma: current status.Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.Soluble markers for diagnosis of malignant pleural mesothelioma.Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma.Biomarkers in the prevention and follow-up of workers exposed to asbestos.Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer

P2860

Q26860736-CD1F8517-A013-47AD-BFC0-FCE873507447 Q28082088-889B81AA-AC6F-49DE-B971-6EF9E7387B07 Q28254804-BA29EBDB-64B3-42F9-A93B-89EE8C1BD824 Q28387447-F85A761A-96E9-492E-9D80-25B94FC2D043 Q28535472-C4978DA3-E570-4AA3-89B5-FAD83BE7C757 Q34513958-DCE7BEE5-53E9-434A-84E6-AA1A85995191 Q34614847-2F548DB6-0833-4714-9FC5-C8878F39F90D Q35323396-5D2A12A1-31C2-419D-8745-684D02B4E685 Q35904195-7E50A717-8737-4DF6-87CD-7FDF36EFB077 Q37176647-06E14E30-B4A9-40B0-9C74-9D3817DF07EA Q37328307-0A9575EB-C2E1-4B4E-8691-2B25E92867D9 Q37335377-08D108C8-5A7B-4517-8C3A-62449EB8D5AB Q37612152-63332EE9-127D-4D35-910B-EA5B3104BF8F Q37862752-1BE86377-6592-4149-BC89-F6EDBD21A5CA Q38118298-9DB168DA-026D-4647-A0D6-D84DC1B24B72 Q47153393-08B90D49-0F20-42DE-B36D-B383C2D2C0BD Q52672882-ACE07361-65C1-4040-BE27-65E6DA6E458E Q58128443-4AAEF244-C95B-49B3-84A9-4F302FF8FFDC

P2860

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin

http://www.wikidata.org/entity/Q28275451

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Megakaryocyte potentiating fac ...... in comparison with mesothelin

@ast

Megakaryocyte potentiating fac ...... in comparison with mesothelin

@en

Megakaryocyte potentiating fac ...... in comparison with mesothelin

@nl

type

label

Megakaryocyte potentiating fac ...... in comparison with mesothelin

@ast

Megakaryocyte potentiating fac ...... in comparison with mesothelin

@en

Megakaryocyte potentiating fac ...... in comparison with mesothelin

@nl

prefLabel

Megakaryocyte potentiating fac ...... in comparison with mesothelin

@ast

Megakaryocyte potentiating fac ...... in comparison with mesothelin

@en

Megakaryocyte potentiating fac ...... in comparison with mesothelin

@nl

P1433

Q28275451-E29C195C-6265-4F73-BA86-D44679B90AB8

P1476

Q28275451-75B5B054-C518-48F2-8535-EF4CC25E60F7

P2093

Q28275451-0C9B2013-EC15-41AE-BE72-2A16A1714519

Q28275451-0DCF6548-2B18-4E4C-978A-E2802BB2E71A

Q28275451-1C4C4A11-D4FA-42C7-8066-D1AB4BAA4D04

Q28275451-1EF6CCD6-4223-4540-B418-9CEB9A0503D2

Q28275451-2A11EA3D-B7E3-43F3-B13E-DD14DBB505D6

Q28275451-30496F21-67F7-4716-9FD2-B9EBD064D13D

Q28275451-38233378-DCF3-43BC-8D71-E138333D254B

Q28275451-448ACCEB-0309-4274-A086-E6C70468F8C7

Q28275451-A87B11C8-51A2-4503-BE90-E6356CDDE405

Q28275451-AAC09910-BA2F-46FE-ABDE-7886B96B61C9

P304

Q28275451-3F2B9E3F-4EAC-40BB-AD4B-A0F962A46FBD

P31

Q28275451-4FCC61F8-836F-4DD1-8DFC-189F1F732E21

P356

Q28275451-CCD010F5-2156-41FD-A5AF-CA164F811724

P407

Q28275451-3E204F5B-7D3E-4B90-A3D5-02962F91A686

P433

Q28275451-A53F7815-A9E3-46F8-8CD5-CEFD81AAAE96

P478

Q28275451-BA4E986B-8197-4838-8758-0B185E921251

P577

Q28275451-5DA24D9C-5316-424E-B1B4-2ADB507BE5F0

P698

Q28275451-B4026949-A514-4EF7-8DD8-D30A9BC980D2

P356

J.LUNGCAN.2008.02.012

P1433

P1476

Megakaryocyte potentiating fac ...... in comparison with mesothelin

@en

P2093

Akihito Yokoyama

http://www.w3.org/2001/XMLSchema#string

Hidekazu Suzuki

http://www.w3.org/2001/XMLSchema#string

Hironobu Hamada

http://www.w3.org/2001/XMLSchema#string

Ichiro Kawase

http://www.w3.org/2001/XMLSchema#string

Isao Tachibana

http://www.w3.org/2001/XMLSchema#string

Kaoru Matsui

http://www.w3.org/2001/XMLSchema#string

Kentaro Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Kota Iwahori

http://www.w3.org/2001/XMLSchema#string

Minoru Fujimoto

http://www.w3.org/2001/XMLSchema#string

Satoshi Serada

http://www.w3.org/2001/XMLSchema#string

P304

45-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LUNGCAN.2008.02.012

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18394747

http://www.w3.org/2001/XMLSchema#string